Kalundborg Bioenergy – Ørsted’s industrial biogas plant powered by Novo Nordisk and Novozymes
Kalundborg Bioenergy is a collaboration of Ørsted and Bigadan with Novo Nordisk and Novozymes. The plant will treat 300,000 tonnes of waste from insulin and enzyme production at Novo Nordisk and Novozymes and produce what is equivalent to the annual natural gas consumption of 5,000 households.
Establishing this large scale production of biogas, and the industrial partnership with Ørsted, was made possible because Novo Nordisk and Novozymes have ambitious goals for utilizing waste streams to produce sustainable energy.
Construction started in 2017 and the full-scale plant will be commissioned in the spring of 2018.